On June 22, Sanofi fell 3.19% in regular trading, trading at $40.96/share, with turnover of approximately $19.65 million. The decline extends selling pressure following the company's announcement on June 10 that it would terminate the Phase III MOBILIZE study of its core pipeline asset riliprubart for refractory chronic inflammatory demyelinating polyneuropathy (CIDP).

An independent data monitoring committee's interim analysis indicated the study was unlikely to meet its pre-specified efficacy endpoints. Riliprubart, a humanized IgG4 monoclonal antibody and selective C1s inhibitor, had been projected to achieve peak sales of 2 to 5 billion euros, making it one of Sanofi's most critical growth drivers. The trial failure has disrupted the company's strategy of relying on new product launches to sustain revenue growth as its blockbuster drug Dupixent faces patent cliff pressures. The compounding uncertainty around Sanofi's pipeline continues to weigh on investor sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)